About the LOTIS-9 Study
Trial Name: A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)
ClinicalTrials.gov Indentifier: NCT05144009
Completion Date: February 18, 2030
Recruitment Status: Recruiting
Sponsor: ADC Therapeutics S.A.
Recruitment Contact: 954-903-7994, firstname.lastname@example.org